S100A4 regulates immunosuppressive T cells and myeloid cells in glioblastoma, the deletion of S100A4 in non-tumor cells is sufficient to reprogram the immune landscape and significantly enhance survival rates, indicating its potential as a target for immunotherapy (46). The gene discussed is S100A4; the disease is neoplasm.